Effect of PPARγ Agonist Rosiglitazone on Expression of Matrix Metalloproteinase 2 in Spontaneously Hypertensive Rats

缪培智,顾水明,金贤,汪海娅,方宁远
DOI: https://doi.org/10.3969/j.issn.1008-0074.2008.04.012
2008-01-01
Abstract:Objective:To investigate the effect of peroxisome proliferator-activated receptor γ(PPARγ) agonist-rosiglitazone on the expression and activity of matrix metalloproteinase 2(MMP-2) in heart,renal and artery of spontaneously hypertensive rats(SHR).Methods:The 12 male SHR aged twelve weeks,with body weight of 245~255 g,were randomly divided into two groups: control group and rosiglitazone treated group(rosiglitazone 5 mgkg·d,intragastric administration)(n=6 in each group).After four-week treatment,the expression and activity of MMP-2 in left ventricle,renal cortex,thoracic aorta and carotid artery of all the rats were determined by real time PCR,Western-blot and zymography.Results:After rosiglitazone therapy,the expression of MMP-2 mRNA in left ventricle and renal cortex decreased by 97.6% and 58.9%(P0.01,0.05,respectively),and the activity of MMP-2 in thoracic aorta and carotid artery decreased by 30.7% and 24.6%(P0.05).Conclusion:Rosiglitazone can obviously attenuate the expression and activity of MMP-2,and may be by this way reduces remodeling in SHR.
What problem does this paper attempt to address?